Axon Enterprise, Inc. (NASDAQ:AXON) Stock Holdings Boosted by Tidal Investments LLC

Tidal Investments LLC boosted its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 1,422.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,465 shares of the biotechnology company’s stock after buying an additional 46,215 shares during the period. Tidal Investments LLC owned 0.06% of Axon Enterprise worth $29,398,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AXON. Capital World Investors grew its position in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after buying an additional 841,772 shares in the last quarter. Alliancebernstein L.P. grew its position in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock valued at $659,128,000 after buying an additional 812,337 shares in the last quarter. Norges Bank bought a new position in Axon Enterprise in the 4th quarter valued at about $482,081,000. GQG Partners LLC bought a new position in Axon Enterprise in the 4th quarter valued at about $478,349,000. Finally, Vanguard Group Inc. grew its position in Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock valued at $5,019,886,000 after buying an additional 275,959 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on AXON shares. Needham & Company LLC upped their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Craig Hallum downgraded shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. Northcoast Research downgraded shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a report on Wednesday, February 19th. Barclays upped their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a report on Friday, May 9th. Finally, The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $652.73.

Axon Enterprise Stock Performance

Shares of AXON opened at $733.18 on Friday. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $735.68. The company has a 50-day moving average of $584.61 and a two-hundred day moving average of $594.51. The stock has a market cap of $57.08 billion, a price-to-earnings ratio of 189.45, a PEG ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analysts’ expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same period last year, the company posted $1.15 earnings per share. On average, equities research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeri Williams sold 307 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the sale, the director now owns 1,627 shares of the company’s stock, valued at approximately $899,275.44. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,764 shares of company stock worth $14,856,635. 4.40% of the stock is owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.